Triptolide Inhibits Histone Methyltransferase EZH2 and Modulates the Expression of Its Target Genes in Prostate Cancer Cells

  • Tamgue, Ousman (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Chai, Cheng-Sen (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Hao, Lin (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Zambe, John-Clotaire Daguia (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Huang, Wei-Wei (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Zhang, Bin (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Lei, Ming (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University) ;
  • Wei, Yan-Ming (Key Laboratory of Agricultural Molecular Biology, College of Life Science, Northwest A&F University)
  • 발행 : 2013.10.30


The histone methyltransferase EZH2 (enhancer of zeste homolog 2) plays critical roles in prostate cancer (PCa) development and is a potential target for PCa treatment. Triptolide possesses anti-tumor activity, but it is unknown whether its therapeutic effect relates with EZH2 in PCa. Here we described EZH2 as a target for Triptolide in PCa cells. Our data showed that Triptolide suppressed PCa cell growth and reduced the expression of EZH2. Overexpression of EZH2 attenuated the Triptolide induced cell growth inhibition. Moreover, Triptolide treatment of PC-3 cells resulted in elevated mRNA levels of target genes (ADRB2, CDH1, CDKN2A and DAB2IP) negatively regulated by EZH2 as well as reduced mRNA levelsan of EZH2 positively regulated gene (cyclin D1). Our findings suggest the PCa cell growth inhibition mediated by Triptolide might be associated with downregulation of EZH2 expression and the subsequent modulation of target genes.


  1. Crea F, Hurt EM, Mathews LA, et al (2011). Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer, 10, 40.
  2. Antonoff MB, Chugh R, Borja-Cacho D, et al (2009). Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery, 146, 282-90.
  3. Cao Q, Yu J, Dhanasekaran SM, et al (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27, 7274-84.
  4. Chang CJ, Hung MC (2012). The role of EZH2 in tumour progression. Br J Cancer, 106, 243-7.
  5. Chase A, Cross NC (2011). Aberrations of EZH2 in Cancer. Clin Cancer Res, 17, 2613-8.
  6. Ellis L, Atadja PW, Johnstone RW (2009). Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther, 8, 1409-20.
  7. Etchegaray JP, Yang X, DeBruyne JP, et al (2006). The polycomb group protein EZH2 is required for mammalian circadian clock function. J Biol Chem, 281, 21209-15.
  8. Feldman BJ, Feldman D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer, 1, 34-45.
  9. Fussbroich B, Wagener N, Macher-Goeppinger S, et al (2011). EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One, 6, e21651.
  10. Gil J, Bernard D, Peters G (2005). Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol, 24, 117-25.
  11. Kiviharju TM, Lecane PS, Sellers RG, et al (2002). Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res, 8, 2666-74.
  12. Huang W, He T, Chai C, et al (2012). Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One, 7, e37693.
  13. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  14. Kamminga LM, Bystrykh LV, de Boer A, et al (2006). The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood, 107, 2170-9.
  15. Liu J, Jiang Z, Xiao J, et al (2009). Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine, 16, 1006-13.
  16. Min J, Zaslavsky A, Fedele G, et al (2010). An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med, 16, 286-94.
  17. O'Carroll D, Erhardt S, Pagani M, et al (2001). The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol, 21, 4330-6.
  18. Phillips PA, Dudeja V, McCarroll JA, et al (2007). Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res, 67, 9407-16.
  19. Plath K, Fang J, Mlynarczyk-Evans SK, et al (2003). Role of histone H3 lysine 27 methylation in X inactivation. Science, 300, 131-5.
  20. Ren SC, Chen R, Sun YH (2013). Prostate cancer research in China. Asian J Androl, 15, 350-3.
  21. Shi B, Liang J, Yang X, et al (2007). Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol, 27, 5105-19.
  22. Saramaki OR, Tammela TL, Martikainen PM, et al (2006). The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer, 45, 639-45.
  23. Sauvageau M, Sauvageau G (2010). Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell, 7, 299-313.
  24. Schulz WA, Hatina J (2006). Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med, 10, 100-25.
  25. Su IH, Basavaraj A, Krutchinsky AN, et al (2003). Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol, 4, 124-31.
  26. Su IH, Dobenecker MW, Dickinson E, et al (2005). Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell, 121, 425-36.
  27. Titov DV, Gilman B, He QL, et al (2011). XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol, 7, 182-8.
  28. Varambally S, Dhanasekaran SM, Zhou M, et al (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-9.
  29. Wang Y, Lu JJ, He L, et al (2011). Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS One, 6, e23993.
  30. Wang Z, Jin H, Xu R, et al (2009). Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med, 41, 717-27.
  31. Yu J, Yu J, Mani RS, et al (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17, 443-54.
  32. Westerheide SD, Kawahara TL, Orton K, et al (2006). Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem, 281, 9616-22.
  33. Wu SC, Zhang Y (2011). Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J Biol Chem, 286, 28511-9.
  34. Yu J, Cao Q, Mehra R, et al (2007). Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell, 12, 419-31.
  35. Zhao F, Chen Y, Zeng L, et al (2010). Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol, 646, 1-11.
  36. Zhao F, Chen Y, Li R, et al (2010). Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology, 267, 70-9.
  37. Zhu W, Ou Y, Li Y, et al (2009). A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol, 75, 812-9.

피인용 문헌

  1. Roles of E-Cadherin (CDH1) Genetic Variations in Cancer Risk: a Meta-analysis vol.15, pp.8, 2014,
  2. Mechanistic Studies of Cyclin-Dependent Kinase Inhibitor 3 (CDKN3) in Colorectal Cancer vol.16, pp.3, 2015,
  3. Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3β/β-catenin pathway vol.47, pp.5, 2015,
  4. Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors vol.5, pp.33, 2015,
  5. The CDH1 -160C/A polymorphism is associated with breast cancer: evidence from a meta-analysis vol.14, pp.1, 2016,
  6. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants vol.77, pp.6, 2017,
  7. Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3 vol.143, pp.10, 2018,
  8. Triptolide, A Potential Autophagy Modulator pp.1993-0402, 2018,
  9. Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity pp.1573-501X, 2019,